Best of Biotech – the life science businessplan competition

http://www.bestofbiotech.at/

Why participate?

  • Develop your innovation into a business idea and a professional business plan
  • Benefit from professional training and feedback from experts during workshops, one-on-one meetings, coaching sessions and the jury meeting
  • Be recognized in the life science community with a business concept evaluated by a renowned, international jury
  • Win the competition and cash in €15,000 for the best business plan, €10,000 for the 2nd best, €5,000 for the 3rd best, €10,000 for the best medical technology business plan and/or €1,500 as one of the best three business ideas!
  • Expand your entrepreneurial network during the competition with other founders, BOB alumni and the life science expert and financing community
 Who can participate?
  • Students, post-graduates, experienced scientists and other creative individuals who wish to translate their promising and marketable life science innovation into a business idea and a professional business plan.
  • Life sciences include the following areas:
    • Red biotechnology (Biopharmaceuticals for humans or animals)
    • Green or blue biotechnology (Agro-biotechnology or marine biotechnology)
    • White biotechnology (Biotechnology applied to industrial processes)
    • Medical Technology/Medical Devices
    • Supply and service applications in the life sciences (e.g. new sequencing methods, bioinformatics)
  • BOB is open to individuals and teams from all countries. If you participate in phase 2 of the competition, be prepared to travel to Vienna in October 2012 to personally present your business plan to the jury. Though not obligatory, attendance at the workshop, the one-on-one meetings, the coaching session and the award ceremonies/networking events is highly recommended.
  • Entities that have already been incorporated may participate as long as they are not older than 1 year at the submission deadline of the respective phase.
Angehängte Dateien:

BOB_Folder.pdf

Zu diesem Artikel gibt es noch keine Kommentare (Kommentare abonnieren (RSS) oder URL Trackback)

Kommentare sind leider nicht erlaubt.